Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Derivation of an intrinsic brain activity biomarker for the earliest prediction of cognitive decline.

Scientific reports·2026
Same author

RNACOREX - RNA coregulatory network explorer and classifier.

PLoS computational biology·2025
Same author

Conformal inference for reliable single cell RNA-seq annotation.

Bioinformatics (Oxford, England)·2025
Same author

Discovering Genetic Variants in Hypertrophic Cardiomyopathy With Multiple Machine Learning Techniques.

IEEE transactions on computational biology and bioinformatics·2025
Same author

KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients.

Scientific reports·2025
Same author

BN-BacArena: Bayesian network extension of BacArena for the dynamic simulation of microbial communities.

Bioinformatics (Oxford, England)·2024

Related Experiment Video

Updated: May 25, 2026

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Ensemble transcript interaction networks: a case study on Alzheimer's disease.

Rubén Armañanzas1, Pedro Larrañaga, Concha Bielza

  • 1Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Madrid, Spain. r.armananzas@upm.es

Computer Methods and Programs in Biomedicine
|January 28, 2012
PubMed
Summary
This summary is machine-generated.

Computational intelligence (CI) reveals new Alzheimer's disease (AD) insights by analyzing gene expression. This systems biology approach identifies novel transcript networks and metabolic pathways crucial for AD pathogenesis.

More Related Videos

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Related Experiment Videos

Last Updated: May 25, 2026

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Area of Science:

  • Neuroscience
  • Computational Biology
  • Genomics

Background:

  • Systems biology is gaining traction in neurology for holistic analysis.
  • Computational intelligence (CI) offers ensemble techniques to uncover novel findings.

Purpose of the Study:

  • To apply a CI approach using ensemble Bayesian networks for Alzheimer's disease (AD) transcript profiling.
  • To identify probabilistic biological relationships and unveil new insights into AD pathogenesis.

Main Methods:

  • Utilized ensemble Bayesian network classifiers and multivariate feature subset selection.
  • Analyzed high-throughput transcript profiling data from Alzheimer's disease (AD) patients and controls.
  • Compared gene expression in entorhinal cortex (EC) and dentate gyrus (DG) samples.

Main Results:

  • Disclosed novel transcript interaction networks and genes not previously linked to AD.
  • Identified transcripts crucial for other neurological pathologies.
  • Confirmed the relevance of identified transcripts using non-parametric tests.

Conclusions:

  • The CI ensemble approach successfully identified key metabolic mechanisms in AD.
  • This method offers potential for new discoveries in AD pathogenesis and development.
  • Highlights the utility of computational intelligence in neurological systems biology research.